Skip Nav Destination
Abstract CT187: Overall survival (OS) by response during “induction” from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC)
Cancer Res (2021) 81 (13_Supplement): CT187.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
- A. Yu. Pavlov
- A. G. Dzidzariya
- R. A. Gafanov
- I. I. Khalil'
- A. R. Vashurin
Cancer Urology (2022) 17 (4): 124.
Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
- Brian W. Labadie
- Arjun V. Balar
- Jason J. Luke
Cancers (2021) 13 (21): 5415.